Clinical research organization inVentiv Health is strengthening its healthcare research and analytics offerings by acquiring two businesses from IMS Health under an agreement announced Tuesday.
IMS is divesting the two business units as a condition of an acquisition of its own. IMS last January announced a deal to acquire SDI Health, a Pennsylvania healthcare analytics firm. The deal closed in October. But in order to receive regulatory approval, IMS agreed to sell SDI’s promotional and medical audit business units.
The two businesses that inVentiv is acquiring will become part of Campbell Alliance, the Raleigh-based pharmaceuticals consultancy that itself was an inVentiv acquisition last year. No financial terms for any of the deals were disclosed.
“This is an important step in boosting inVentiv’s capabilities in market research and analytics,” inVentiv CEO Paul Meister said in a statement. “In combination with our leading consulting services, these additional capabilities allow us to provide a more comprehensive offering that augments our clients’ business decision-making.”
Burlington, Massachusetts-based inVentiv was acquired in 2010 for $1.1 billion by private equity firm Thomas H. Lee Partners in a deal that took the CRO private, one example of the strong interest that private equity has taken in the CRO sector. Since that deal, inVentiv has become particularly active in making M&A deals. Besides the Campbell Alliance acquisition, inVentiv has also acquired CRO i3 as well as Pharmanet Development Group. InVentiv has 13,000 employees working in 40 countries.
Acquisition of the SDI businesses is subject to customary closing conditions and approval by the Federal Trade Commission, following a public comment period. The deal is expected to close in February.
Get the latest news alerts: Follow WRAL Tech Wire at Twitter.